TLX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

10.160

Open

10.010

VWAP

10.07

Vol

90.46K

Mkt Cap

3.42B

Low

9.950

Amount

910.65K

EV/EBITDA(TTM)

176.49

Total Shares

338.78M

EV

7.20B

EV/OCF(TTM)

--

P/S(TTM)

4.27

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Show More

Events Timeline

(ET)

2026-06-02

07:20:00

Telix Pharmaceuticals Signs MOU with United Imaging for Strategic Collaboration

2026-05-18 (ET)

2026-05-18

17:10:00

Telix Pharmaceuticals Completes Patient Enrollment for TLX101-Tx Study

2026-05-15 (ET)

2026-05-15

06:40:00

Telix Pharmaceuticals Enters into Collaboration Letters of Intent with EDAP and Profound Medical

2026-05-04 (ET)

2026-05-04

17:20:00

Telix Pharmaceuticals Publishes New Analysis of ZIRCON Trial

2026-04-30 (ET)

2026-04-30

17:50:00

Telix Pharmaceuticals Files MAA for TLX101-Px Marketing Authorization

2026-04-14 (ET)

2026-04-14

19:10:00

Telix Pharmaceuticals Doses First Patient with TLX101-Tx in Brain Cancer Trial

2026-04-13 (ET)

2026-04-13

06:40:00

Telix and Regeneron Collaborate to Develop Radiopharmaceuticals

2026-04-13

06:40:00

Telix Pharmaceuticals Up 11% to $11.70 After Collaboration with Regeneron

2026-04-09 (ET)

2026-04-09

19:00:00

Telix Pharmaceuticals' TLX101-Px New Drug Application Accepted by FDA

News

NASDAQ.COM

06-02NASDAQ.COM

Telix Pharmaceuticals and United Imaging Sign Strategic Collaboration MOU

Newsfilter

06-01Newsfilter

Telix's TLX591-Tx Shows Promising Results in Prostate Cancer Trials

Newsfilter

05-18Newsfilter

Telix Completes Patient Enrollment for TLX101-Tx Clinical Trial

Newsfilter

05-15Newsfilter

Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments

Newsfilter

05-04Newsfilter

Telix Publishes ZIRCON Trial Data Analysis Indicating High Predictive Value of TLX250-Px

NASDAQ.COM

05-01NASDAQ.COM

Telix Pharmaceuticals Presents TLX597-Tx Dosimetry Data from Phase 2 Trial

Valuation Metrics

The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX.O) is 2000.00, compared to its 5-year average forward P/E of 653.73. For a more detailed relative valuation and DCF analysis to assess Telix Pharmaceuticals Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

653.73

Current PE

2000.00

Overvalued PE

1595.44

Undervalued PE

-287.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

49.11

Current EV/EBITDA

54.81

Overvalued EV/EBITDA

64.00

Undervalued EV/EBITDA

34.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.34

Current PS

2.15

Overvalued PS

6.64

Undervalued PS

2.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

technology or even medical

Intellectia · 3 candidates

Sector: Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical Research, Software & IT Services, Technology, Technology EquipmentPrice Change Pct: $3.00 - $100.00Relative Vol: >= 1.20News Driver: Positive, Negative

Ticker

Name

Market Cap$

CoreWeave Inc

53.62B

Telix Pharmaceuticals Ltd

3.57B

Marvell Technology Inc

112.34B

stocks with highest short ratio

Intellectia · 11 candidates

Market Cap: >= 1000.00MRelative Vol: >= 1.20Short Ratio: MoreThan30PctWeekly Average Turnover: >= 1,000,000Month Price Change Pct: <= $-2.00

Ticker

Name

Market Cap$

Expedia Group Inc

33.27B

Willis Towers Watson PLC

30.55B

AXIS Capital Holdings Ltd

7.96B

Birkenstock Holding PLC

7.24B

MakeMyTrip Ltd

6.22B

Pampa Energia SA

4.48B

Whales Holding TLX

Sanlam Investments Uk Limited

Challenger Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Telix Pharmaceuticals Ltd (TLX) stock price today?

The current price of TLX is 10.09 USD — it has increased 1.51

What is Telix Pharmaceuticals Ltd (TLX)'s business?

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

What is the price predicton of TLX Stock?

Wall Street analysts forecast TLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Telix Pharmaceuticals Ltd (TLX)'s revenue for the last quarter?

Telix Pharmaceuticals Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Telix Pharmaceuticals Ltd (TLX)'s earnings per share (EPS) for the last quarter?

Telix Pharmaceuticals Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Telix Pharmaceuticals Ltd (TLX). have?

Telix Pharmaceuticals Ltd (TLX) has 0 emplpoyees as of June 21 2026.

What is Telix Pharmaceuticals Ltd (TLX) market cap?

Today TLX has the market capitalization of 3.42B USD.